DB05880ExperimentalSmall molecule
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
- Mechanism
- Curator reviewed
The already approved and accepted therapy of anti-angiogenesis (suppressing tumor vascularization), is complemented by MBT-0312. An innovative proprietary carrier system of lipid complexes facilitates a novel application method of established cytostatic drugs (e.g. Taxane), intended to cause specific attachment and destruction of tumor blood vessels ("neovascular targeting").
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- MBT-0312
Which companies are running trials of MBT-0312, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account